Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease "COMPASS"
Active, not recruiting
Phase 3 Results N/ASummary of Purpose
The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 26 March 2018.
28 Feb 2013 | 24 Jan 2013 | 21 Jul 2017 | 30 Jun 2021 | 1 Mar 2018 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Prevention
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
- Bayer Clinical Trials Contact
- For Trial Location Information (Phone Menu Options '3' or '4')
(+)1-888-84 22937
View Trial Locations
Recruitment
- Enrollment: 27,395
- Gender: All
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 672 locations, 34 countries
Principal Investigator
- Bayer Study Director
Bayer